The future cobas® Mass Spec analyser*

* cobas® i 601 analytical unit (Mass Spec) is not yet available for sale in the UK and Ireland.

Step into the future with our mass spectrometry analyser

Catch a glimpse of our future fully automated, standardised liquid chromatography-mass spectrometry (LC-MS) solution: the cobas® Mass Spec.

Recently unveiled at EuroMedLab 2023, our mass spectrometry analyser is designed to seamlessly integrate into clinical chemistry and immunochemistry testing as part of cobas® pro integrated solutions, as well as lab automation & IT.** Are you as thrilled as we are about this innovative solution? Stay informed by subscribing to our updates.

 

Keep me updated
mass analyzer

Subscribe for updates on cobas® Mass Spec

Register now to receive the latest launch updates.

Imagine a new dimension in mass spectrometry with cobas® Mass Spec solution - the cobas® i 601 analytical unit and the Ionify® reagent line* 

Join us on this journey and discover new possibilities for your lab. With a planned broad in-vitro diagnostics (IVD) testing menu, it is designed to replicate the user experience of established immunoassay or clinical chemistry analysers.

Form Successfully Submitted!
Thank you for your submission!
text
Close

If you could dream up a clinical laboratory of the future, what would it look like?

This solution has the potential to bring the core lab of the future to life. Watch this informative video that showcases the cobas® Mass Spec solution—designed to be a fully integrated, high-throughput system with an extensive menu, at launch.


Join us on this journey and discover new possibilities for your lab.

Fully integrating mass spec into the routine laboratory

Mass spectrometry today

Mass spectrometry is renowned for its high sensitivity, specificity and accuracy and is therefore considered the gold standard in several clinical indications.1-7

Research8 shows that many clinical laboratories would like to benefit from mass spectrometry in order to expand and enhance their test offering, but struggle to do so due to various limitations of the existing solutions on the market.

  • High technology and operational complexity
  • High manual burden, lack of integration and standardisation
  • The need for highly specialised and trained expert staff

 

The future of mass spectrometry from Roche*

Using feedback from customers, Roche is developing a true technological revolution – an entirely automated clinical mass spectrometry solution for the routine lab.

 

cobas Mass Spec* is designed to have: 

Seamless integration

into clinical chemistry and immunochemistry testing as a part of cobas® pro integrated solutions as well as lab automation and IT

Full automation

From sample preparation to results interpretation with random access operation

High throughput

To fit the needs of the routine laboratory for fast and predictable turnaround times – up to 100 samples/hour

Broad assay menu

Consolidated on a single platform with standardised performance traceable to reference methods, >60 analytes planned

Sign up to stay in touch

Join our mailing list to learn more about cobas®  Mass Spec solution and to receive up-to-date information about its availability in your region.

Form Successfully Submitted!
Thank you for your submission!
text
Close

Read more

...
    ...

    *cobas® i 601 analytical unit (Mass Spec) is not yet available for sale in the UK and Ireland. Contact the local Roche Diagnostics representative for more information.

    ** At launch cobas® Mass Spec will be available in a stand-alone configuration only. All other configurations including clinical chemistry and immunochemistry analytical units will be available at a later date.

    References

    1. Handelsman, D. J. Mass spectrometry, immunoassay and valid steroid measurements in reproductive medicine and science. Hum Reprod 32, 1147-1150 (2017). TDM (4,5,8,9,12-14).
    2. De Rose, D. U. et al. Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age. Int J Mol Sci 21, (2020).
    3. Gong, Z. S. et al. A high-throughput LC-MS/MS method for the quantification of four immunosuppressant drugs in whole blood. Clin Chim Acta 498, 21-26, (2019).
    4. Hörber, S., Peter, A., Lehmann, R. & Hoene, M. Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS/MS-based clinical analyzer suggests a new era in laboratory medicine. Clin Chem Lab Med, (2020).
    5. McShane, A. J., Bunch, D. R. & Wang, S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry. Clin Chim Acta 454, 1-5, (2016).
    6. Zhang, Y. & Zhang, R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. Drug Test Anal 10, 81-94, (2018).
    7. Sommerfeld-Klatta, K., Zielińska-Psuja, B., Karaźniewcz-Łada, M. & Główka, F. K. New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs). Molecules 25, (2020).
    8. Business potential of clinical Mass Spectrometry, usage of CMS in Seven target countries. Study number 40846131.